BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open’s open peer review process please email info.bmjopen@bmj.com
| Journal:  | BMJ Open |
|----------|----------|
| Manuscript ID: | bmjopen-2021-050910 |
| Article Type: | Original research |
| Date Submitted by the Author: | 04-Mar-2021 |
| Complete List of Authors: | Ferrari, Emile; Nice University Hospital, Cardiology Department 
Fourrier, Etienne; University Hospital Centre Nice Pasteur Hospital, Cardiology 
Asarisi, Florian; University Hospital Centre Nice Pasteur Hospital, Cardiology 
Heme, Nathan; University Hospital Centre Nice Pasteur Hospital, Cardiology 
Redjimi, Nassim; University Hospital Centre Nice Pasteur Hospital, Cardiology 
Berkane, Nathalie; Centre Hospitalier de Cannes, Cardiology 
Labbaoui, Mohamed; CHU Nice, Cardiology 
Breittmayer, Jean Philippe; University Hospital Centre Nice Pasteur Hospital, Cardiology 
Bun, Sok Sithikun; University Hospital Centre Nice Pasteur Hospital, Cardiology 
MOCERI, Pamela; Université Côte d'Azur, UR2CA, CHU de Nice, Cardiology Department 
Squara, Fabien; Hopital Pasteur, Cardiology |
| Keywords: | Echocardiography < CARDIOLOGY, Adult cardiology < CARDIOLOGY, Thromboembolism < CARDIOLOGY |
I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author’s Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.
Higher risk of pulmonary embolism recurrence when the first event is severe. A cohort study.

Short title: PE severity and recurrence risk

Emile FERRARI, MD\textsuperscript{a}; Etienne FOURRIER, MD\textsuperscript{a}; Florian ASARISI, MD\textsuperscript{a}; Nathan HEME, MD\textsuperscript{a};

Nassim REDJIMI, MD\textsuperscript{a}; Nathalie BERKANE, MD\textsuperscript{b}; Mohamed LABBAOUI, MD\textsuperscript{a};

Jean Philippe BREITTMAYER, PhD\textsuperscript{a}; Sok Sithikun BUN, MD PhD\textsuperscript{a},

Pamela MOCERI, MD PhD\textsuperscript{a,c}; Fabien SQUARA, MD\textsuperscript{a,c}.

\textsuperscript{a} Cardiology Department, Centre Hospitalier Universitaire de Nice, Nice, France

\textsuperscript{b} Cardiology Department, Centre Hospitalier de Cannes, Cannes, France

\textsuperscript{c} UR2CA, Université Côte d’Azur, Nice, France

Corresponding author: Prof. Emile FERRARI – CHU de Nice, Cardiology Department

30, Avenue de la voie romaine - CS 51069 - 06001 Nice Cedex 1, France. e-mail: ferrari.e@chu-nice.fr

Conflicts of Interest: None

No previous presentation / abstract / publication

Key words: pulmonary embolism. Epidemiology. Echocardiography. Biomarkers.

Word count: 1589
Abstract.

Objectives: Severity of a first pulmonary embolism (PE) is sometime proposed as a criterion for prolonging anticoagulant treatment. However, little evidence supports this idea. We attempted to determine the connection between severity of first PE and the risk of recurrence.

Method: Patients admitted with PE between 2012 and 2018 and for which anticoagulant treatment had been discontinued were followed. PEs were classified according to severity into 2 groups: 1) those with associated cardiac involvement if the biomarkers were positive and in the presence of right ventricular dysfunction, and 2) those with no cardiac involvement. Recurrence-free survivals were estimated using the Kaplan Meier method and compared using the Log Rank test.

Results: 417 PEs (186 with cardiac involvement, 231 without) were followed for a least one year after discontinuation of anticoagulant treatment with a mean follow-up of: 3.5 ± 1.9 years. 72 patients (17.3%) experienced venous thromboembolism recurrence (5.8%, 12 %, 28.3 %, respectively, at 1, 2 and 5 years). In 63 patients (88%), recurrence was a PE. Mean time to onset of recurrence was 24.9 ±19.9 months. At 5 years, the recurrence rate was higher when the first PE was severe: p=0.043. When the first PE was unprovoked, no difference was found between recurrence rates according to the degree of initial PE severity: p=0.27. In contrast, in patients with provoked PE, the recurrence rate was higher when the first PE event was severe: p=0.032.

Conclusion: We report, for the first time, a higher recurrence rate when the first PE was severe with a recurrence rate of 9% vs 3% and of 35.5% vs 26% at 1 and 5 years respectively: p=0.043. The correlation between PE severity and risk of recurrence was stronger in cases of provoked PE: p=0.032.
Contributorship statement:

EF and EF wrote the protocol and the designed the study.

EF, NR, NB, MB, SB, PM followed up patients who were all reviewed with a long follow-up.

EF, FA, NH collected the data

JP B and FS did the statistics
Article summary

Strengths of our study:

We describe for the first time a link between the severity of the first PE and the recurrence risk with a higher rate of recurrence when the first PE is severe.

This relation is even stronger when the first PE is provoked.

The clinical impact could be significant as it may indicate that the severity of a first PE should be taken into account in the choice of the duration of treatment.

Limitations:

Our study is not randomized.

In our cohort, some patients were long-term anticoagulated and were therefore excluded. This exclusion may have skewed the result of the non-provoked PEs sub-group for which the relationship between initial severity and risk of recurrence is paradoxically less strong than in the group of the provoked PEs.
**Background**

After the acute event, the choice of the duration of treatment is one of the main problems in the management of a first PE. Currently, provoked versus non-provoked circumstance is the main criterion used to determine treatment duration. Alongside this main criterion, other factors can also be taken into account such as bleeding risk, sex, blood group, persistence of a venous clot or the end-of-treatment D-dimers level. Some practitioners consider first PE severity as a criterion likely to extend treatment duration. However, very few findings in the literature corroborate this idea.

**Objective and methods**

Drawing on our regional database, we made a prospective assessment of the connection between first PE severity and the risk of recurrence of VTE events. All patients hospitalized for PE from 2012 to 2018 were followed prospectively. Only patients whose treatment had been discontinued and for which we had a minimum 12-month follow-up were included. Consequently, patients requiring long-term anticoagulant treatment were excluded, along with patients with active cancer.

Patients were divided into two groups:

1) PE with cardiac involvement: in the presence of hemodynamic instability, increased cardiac biomarkers: Troponin I (Tp) > 70 ng/l and/or BNP > 100 pg/ml and/or right ventricular (RV) dysfunction corresponding to intermediate or high-risk PE in the European Society of Cardiology (ESC) classification. High-sensitivity Tp and BNP were measured with Siemens Centaur® and the Alere Triage BNP kit (Beckman Coulter®), respectively. The positivity threshold was 70 ng/l for Tp and 100 pg/ml for BNP. RV dysfunction was defined by echocardiography when a right-to-left ventricular end-diastolic diameter ratio > 0.9 in the apical four-chamber view or > 0.7 in the parasternal long-axis view, a tricuspid annular plane systolic excursion (TAPSE) < 16 mm or a tricuspid annular peak systolic velocity (S'-DTI) < 10 cm/s were observed.
2) PE with no cardiac involvement when none of the above-mentioned criteria were present corresponding to low-risk PE according to the ESC classification.

All chest CT-scans were reread by one radiology expert blinded to the first reading. Special emphasis was placed on eliminating patients with pre-existing pulmonary hypertension as revealed by the patient’s medical history or a search for specific signs on the initial scan such as the presence of arterial webs, mural thrombi or a mosaic parenchymal perfusion. Recurrences were determined by a new venous thrombotic event or by a symptomatic PE confirmed by diagnostic imaging and combined with non-negative D-dimers. If patients presented several recurrences during follow-up, only the first was taken into account. A minimum 12-month follow-up was required although a recurrence within this 12-month period was considered as an event. Mean follow-up was 3.5 ±1.9 years.

**Patient and public involvement:** This case control study was not suitable for a partnering with patients, their carers, support networks, and the public. Patients were not involved in this study.

**Statistical analysis:**

All statistical analyses were performed using SPSS software (Statistical Package for Social Science software, version 20, Chicago, Illinois, USA). Quantitative variables were expressed as means ± standard deviation and qualitative variables as count as percentages. Quantitative variables were compared using the Student t test and qualitative variables were compared using the Chi2 test. Recurrence-free survivals were estimated using the Kaplan Meier method and compared using the Log-Rank test. IRB approval was obtained.

**Results**

Between 2012 and 2018, 1080 patients were hospitalized for PE confirmed by CT-scan. One hundred sixty-four (164) patients had a history of VTE and had received long-term treatment; 113 had active
neoplasia, 104 supraventricular arrhythmia requiring anticoagulant treatment and 91 a cause making follow-up impossible (Figure 1: Flow chart). In all, 417 patients with a follow-up exceeding 12 months after discontinuation of their anticoagulation treatment were included. Among these, 231 had presented PE without cardiac involvement and 186 PE with cardiac involvement (165 intermediate risk PE and 21 high-risk PE). The cohort’s initial characteristics are summarized in Table 1.

A factor explaining the first PE event was found in 50.8% of cases. Associated deep vein thrombosis (DVT) was observed in 44.6% of patients. All provoked PE were treated for 3 months. All unprovoked PE were treated for at least 6 months. Mean treatment duration was 5.18 ±2.3 months. Twenty-one patients (5%) received thrombolysis. Patient characteristics according to the severity of the initial clinical presentation are shown in Table 2. Patients in the PE group with cardiac involvement were more often diabetic (18% v 9%), more often presented blood clots in the lower limbs (51% vs 39%) and averaged longer hospital stays (7.3 ±4 days vs 3.7 ±3 days) than patients without cardiac involvement.

Among the entire cohort, 72 patients (17.3%) presented VTE recurrence. The VTE recurrence rate after discontinuation of anticoagulation was 5.8% the first year, 12% at 2 years and 28.3% at 5 years. In patients experiencing recurrence, 88% (n=63) suffered PE and 12% (n=9) suffered proximal DVT. Mean time to onset of recurrence was 24.9 ± 19.9 months. Kaplan Meier analysis of the entire cohort shows the survival rate of recurrence-free patients according to initial severity over a 5-year follow-up (Fig. 2). The recurrence-free survival rate was significantly higher when the first PE was non-severe p=0.043.

Twelve months after completion of the anticoagulant treatment, the recurrence rate was 7/231 (3%), in the non-cardiac involvement group versus 17/186 (9.1%), in the cardiac involvement group: p=0.007.

Figure 3 compares the survival rates with no VTE recurrence according to the provoked or unprovoked nature of the first PE. In the sub-group of patients presenting an unprovoked PE, Kaplan Meier analysis revealed no difference in recurrence rate according to first PE severity: p=0.27. On the other hand, (Fig. 4), a higher recurrence rate was noted in the sub-group of patients with a severe provoked PE:
p=0.032. At 12 months, recurrence rates were, respectively, 2/112 (1.8%) when there was no initial cardiac involvement versus 9/100 (9%) when cardiac involvement was observed; p=0.018. Regarding other recurrence risk factors: the unprovoked nature of the initial PE was associated with an over-risk of recurrence (HR 1.99 (CI 95%: 1.12-3.33)), as was the presence of associated DVT (HR 1.82 (CI 95%: 1.13-3.1)).

Discussion

After the acute phase, the duration of anticoagulation treatment raises one of the major problems in PE management. Some features have been correlated with an added risk of recurrence and are taken into account when choosing a longer treatment. Other criteria are considered although their connection with increased risk of recurrence has not been formally proven. However, to our knowledge, no study has assessed the benefits of pursuing anticoagulant treatment relative to first PE severity. We thought it would be useful, in a prospective cohort study, to look for a relationship between the severity of the initial PE and the recurrence rate. In the present study including 417 patients followed for a mean of 42 months, the incidence of recurrence was similar to findings described in the literature. In 88% of cases, recurrence occurred at the same site as the first event. We also observed a well-known added risk of recurrence in cases with unprovoked first PE. We confirm a statistical correlation between the risk of recurrence and the presence of DVT at the time of the first PE.

We describe for the first time a higher recurrence rate when the initial PE was severe with a recurrence rate of 9% vs 3% and 35.5% vs 26%, respectively, at 1 and 5 years: p=0.043. Unexpectedly, the correlation between PE severity and the risk of recurrence was stronger when PE was provoked (p=0.032). The lack of a relationship in our study between severity and recurrence among unprovoked PE could be explained by the fact that we maintained anticoagulation treatment in patients at higher risk of recurrence and consequently these patients were not included in our analysis. It is also possible
that the high rate of spontaneous unprovoked PE recurrences conceals the impact of the severity factor. In the literature, the only data that can come close to our result is that of Grifoni et al\textsuperscript{16} who reported a higher rate of recurrence when, after hospitalisation for PE, a RV dysfunction was still present at discharge from hospital.

The human physiological coagulation system is believed to protect us against the risk of thrombosis. The formation of venous clots in risky situations is not the rule. When a venous clot occurs, our coagulation-fibrinolysis system is supposed to control the situation by limiting its spread. The formation of a large amount of clots, and hence the occurrence of severe PE, could mean that control by the physiological coagulation system is even more failing. It could also provide additional, hitherto unknown, information on a greater propensity for recurrence.

In the literature, the recurrence risk of a provoked PE is deemed to be sufficiently low not to require long-term treatment. Nevertheless, the risk is still much higher than in a control population. The survey of the literature by Iorio et al\textsuperscript{17} covering 2268 provoked PE with transitory risk shows a mean 0.7% annual recurrence rate after surgery but a 3.3% rate for patients as a whole and a 4.2% annual recurrence rate for non-surgical transitory risk factors. These two latter rates are close to the findings for unprovoked thromboembolic events. Our results indicate that in these provoked PE, an over-risk of recurrence could be associated with the severity of the initial event\textsuperscript{2,18-20}.

Conclusion: In this cohort study, we demonstrate a connection between the severity of a first PE and the risk of a subsequent recurrence. The provoked status of PE does not shield against a high recurrence rate when the first event was severe. These findings justify a prospective study designed to confirm this relationship which could change the way we determine the duration of anticoagulation treatment after a first PE.
References

1. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. *N Engl J Med*. 2004;350(25):2558-2563.

2. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. *Haematologica*. 2007;92(2):199-205.

3. Linnemann B, Zgouras D, Schindewolf M, Schwonberg J, Jarosch-Preusche M, Lindhoff-Last E. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. *Blood Coagul Fibrinolysis Int J Haemost Thromb*. 2008;19(2):159-165.

4. Baudouy D, Moceri P, Chiche O, et al. B blood group: A strong risk factor for venous thromboembolism recurrence. *Thromb Res*. 2015;136(1):107-111.

5. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. *N Engl J Med*. 2006;355(17):1780-1789.

6. Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. *JAMA*. 2003;290(8):1071-1074.

7. Ferrari E, Baudouy M, Cerboni P, et al. Clinical epidemiology of venous thromboembolic disease. Results of a French Multicentre Registry. *Eur heart j* 1997; 18: 685-691.
8. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J*. 2020;41(4):543-603.

9. Kearon C, Iorio A, Palareti G, Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. *J Thromb Haemost JTH*. 2010;8(10):2313-2315.

10. Tromeur C, Sanchez O, Presles E, et al. Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial. *Eur Respir J*. 2018;51(1):1701202.

11. Cohen AT, Gitt AK, Bauersachs R, et al. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. *Thromb Haemost*. 2017;117(7):1326-1337.

12. Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. *BMJ*. 2019;366:l4363.

13. Martinez C, Cohen AT, Bamber L, Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. *Thromb Haemost*. 2014;112(2):255-263.
14. Albertsen IE, Nielsen PB, Søgaard M, et al. Risk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. *Am J Med*. 2018;131(9):1067-1074.e4.

15. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. *J Thromb Haemost JTH*. 2010;8(11):2436-2442.

16. Grifoni S, Vanni S, Magazzini S, et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. *Arch Intern Med*. 2006;166(19):2151-2156.

17. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. *Arch Intern Med*. 2010;170(19):1710-1716.

18. Prins MH, Lensing AWA, Prandoni P, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. *Blood Adv*. 2018;2(7):788-796.

19. Ensor J, Riley RD, Moore D, Snell KIE, Bayliss S, Fitzmaurice D. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. *BMJ Open*. 2016;6(5):e011190.

20. Bikdeli B, Jimenez D, Hawkins M, et al. Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). *Thromb Haemost*. 2018;118(1):214-224.
Table 1: Initial cohort characteristics

| Overall population | N = 417 | (%) |
|--------------------|---------|-----|
| Sex F/M, n (%)     | 221     | (53%) |
| Age, years (mean ± SD) | 63.1 (±17.1) |     |
| Arterial hypertension, n (%) | 179 | (43%) |
| Obesity, n (%)     | 74      | (18%) |
| Dyslipidemia, n (%)| 109     | (26%) |
| Diabetes, n (%)    | 55      | (13%) |
| Smoking, n (%)     | 110     | (26%) |
| History of stroke, n (%) | 26 | (6%) |
| Inflammatory disease, n (%) | 33 | (8%) |
| Psychiatric pathology, n (%) | 83 | (20%) |
| Provoked, n (%)    | 212     | (51%) |
| Associated DVT, n (%) | 186 | (45%) |
| Thrombolysis, n (%)| 21      | (5%) |
| Duration of hospital stay, days (mean ±SD) | 5.8 (± 3.8) |
| Initial anticoagulation duration, months (mean ±SD) | 5.18 (± 2.3) |
| Follow-up period, months (mean ± SD) | 42.1 (± 22.8) |
| VTE recurrence, n (%) | 72 | (18%) |
| - PE, n (% of recurrence) | 63 | (88%) |
| - DVT, n (% of recurrence) | 9 | (12%) |
| Time to recurrence, in months, (mean ± SD) | 24.9 (± 19.9) |
Table 2: Initial characteristics of PE groups without and with cardiac involvement

|                           | PE without cardiac involvement | PE with cardiac involvement | P-value |
|---------------------------|-------------------------------|----------------------------|---------|
| N =231                    |                               | N =186                      |         |
| Sex F/M, n (%)            | 113 (48.9)                    | 108 (58.1)                  | 0.074   |
| Age, years (mean ± SD)    | 61 ± 17.2                     | 63 ± 15.5                   | 0.12    |
| Arterial hypertension, n (%) | 90 (39)                       | 89 (48)                     | 0.068   |
| Obesity, n (%)            | 43 (19)                       | 31 (17)                     | 0.622   |
| Dyslipidemia, n (%)       | 53 (23)                       | 56 (30)                     | 0.09    |
| Diabetes, n (%)           | 21 (9)                        | 34 (18)                     | 0.006   |
| Smoking, n (%)            | 72 (31)                       | 38 (20)                     | 0.012   |
| History of stroke, n (%)  | 10 (4)                        | 16 (8.6)                    | 0.073   |
| Inflammatory disease, n (%) | 17 (7)                        | 16 (8.6)                    | 0.187   |
| Psychiatric pathology, n (%) | 45 (20)                      | 38 (20)                     | 0.809   |
| Provoked, n (%)           | 112 (49)                      | 100 (54)                    | 0.284   |
| Associated DVT, n (%)     | 90 (39)                       | 96 (52)                     | 0.01    |
| **Length of hospital stay, days (mean ± SD)** | 4.7 ± 3                       | 7.3 ± 4                     | 0.004   |
| Tp (ng/l)                 | 29.1 ± 16                     | 240 ± 237                   | 0.0001  |
| BNP (pg/l)                | 45 ± 21                       | 243.2 ± 106                 | 0.0001  |
| RV/LV                     | 0.62 ± 0.07                   | 0.96 ± 0.05                 | 0.01    |
| Duration in months of initial anticoagulation | 5.18 ± 2.4                   | 5.2 ± 2.3                   | 0.417   |

RV/LV = right-to-left ventricular end-diastolic diameter ratio > 0.9 in the apical four-chamber view
Figures legends

Figure 1: Study flow-chart

Figure 2: Recurrence-free survival for VTE according to severity of first PE

Figure 3: Recurrence-free survival following provoked PE according to severity of first PE

Figure 4: Recurrence-free survival following unprovoked PE according to severity of first PE
Figure 1

Patients hospitalized with PE from 2012 to 2018
n = 1080

Pre-selected patients n = 671

Included patients n = 417

Non-included patients N = 409
- History of VTE n = 164
- Active neoplasia n = 113
- Supra-ventricular arrhythmia n = 104
- Thrombophilia n = 28

Excluded patients N = 254
- Dementia n = 91
- Lost to follow-up n = 57
- Decease during the first 12 months n = 44
- Other (PHI group IV, advanced degenerative neuropathy or long-term bedridden, or patient wishing to maintain long-term anticoagulation) n = 62

Low-risk PE n = 231
Intermediate-risk PE n = 165
High-risk PE n = 21

PE with no cardiac involvement n = 231
PE with cardiac involvement n = 186
Figure 3

![Recurrence-free survival rate graph]

- PE without cardiac involvement
- PE with cardiac involvement

**Recurrence-free survival rate (%)**

| Time since discontinuation of anticoagulant (years) | PE without cardiac involvement | PE with cardiac involvement |
|---------------------------------------------------|--------------------------------|-----------------------------|
| 0                                                  | 112 (0)                        | 100 (0)                     |
| 1                                                  | 110 (2)                        | 91 (9)                      |
| 2                                                  | 74 (14)                        | 56 (11)                     |
| 3                                                  | 49 (6)                         | 37 (14)                     |
| 4                                                  | 34 (8)                         | 18 (17)                     |
| 5                                                  | 19 (10)                        | 13 (17)                     |

*p = 0.032*
Figure 4

![Graph showing recurrence-free survival rate over time since discontinuation of anticoagulant. The graph compares patients with and without cardiac involvement.](image)

- **PE without cardiac involvement**
  - Time points: 0 (119), 1 (114), 2 (75), 3 (54), 4 (34), 5 (19)

- **PE with cardiac involvement**
  - Time points: 0 (86), 1 (78), 2 (42), 3 (34), 4 (15), 5 (7)

The overall comparison shows no significant difference with a p-value of 0.268.
### STROBE Statement—checklist of items that should be included in reports of observational studies

| Item No | Recommendation |
|---------|----------------|
| **Title and abstract** | 1. (a) Indicate the study’s design with a commonly used term in the title or the abstract  
2. (b) Provide in the abstract an informative and balanced summary of what was done and what was found |
| **Introduction** | |
| Background/rationale | 2. Explain the scientific background and rationale for the investigation being reported |
| Objectives | 3. State specific objectives, including any prespecified hypotheses |
| **Methods** | |
| Study design | 4. Present key elements of study design early in the paper |
| Setting | 5. Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection |
| Participants | 6. (a) **Cohort study**—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up  
(b) **Case-control study**—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls  
(c) **Cross-sectional study**—Give the eligibility criteria, and the sources and methods of selection of participants |
| Variables | 7. Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable |
| Data sources/measurement | 8. For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group |
| Bias | 9. Describe any efforts to address potential sources of bias |
| Study size | 10. Explain how the study size was arrived at |
| Quantitative variables | 11. Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why |
| Statistical methods | 12. (a) Describe all statistical methods, including those used to control for confounding  
(b) Describe any methods used to examine subgroups and interactions  
(c) Explain how missing data were addressed  
(d) **Cohort study**—If applicable, explain how loss to follow-up was addressed  
(e) **Case-control study**—If applicable, explain how matching of cases and controls was addressed  
(f) **Cross-sectional study**—If applicable, describe analytical methods taking account of sampling strategy  
(g) Describe any sensitivity analyses |

Continued on next page
Results

Participants 13*
(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram

Descriptive data 14*
(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
(b) Indicate number of participants with missing data for each variable of interest
(c) Cohort study—Summarise follow-up time (eg, average and total amount)

Outcome data 15*
Cohort study—Report numbers of outcome events or summary measures over time
Case-control study—Report numbers in each exposure category, or summary measures of exposure
Cross-sectional study—Report numbers of outcome events or summary measures

Main results 16
(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
(b) Report category boundaries when continuous variables were categorized
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

Other analyses 17
Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results 18
Summarise key results with reference to study objectives

Limitations 19
Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias

Interpretation 20
Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence

Generalisability 21
Discuss the generalisability (external validity) of the study results

Other information

Funding 22
Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.
Is pulmonary embolism recurrence linked with the severity of the first event? A French retrospective cohort study.

| Journal         | BMJ Open                        |
|-----------------|---------------------------------|
| Manuscript ID   | bmjopen-2021-050910.R1          |
| Article Type    | Original research               |
| Date Submitted by the Author: | 24-Aug-2021                   |
| Complete List of Authors: | Ferrari, Emile; Centre Hospitalier Universitaire de Nice Hospital Pasteur, Cardiology Department  
Fourrier, Etienne; University Hospital Centre Nice Pasteur Hospital, Cardiology  
Asarisi, Florian; University Hospital Centre Nice Pasteur Hospital, Cardiology  
Heme, Nathan; University Hospital Centre Nice Pasteur Hospital, Cardiology  
Redjimi, Nassim; University Hospital Centre Nice Pasteur Hospital, Cardiology  
Berkane, Nathalie; Centre Hospitalier de Cannes, Cardiology  
Labbaoui, Mohamed; CHU Nice, Cardiology  
Breittmayer, Jean Philippe; University Hospital Centre Nice Pasteur Hospital, Cardiology  
Bun, Sok Sithikun; University Hospital Centre Nice Pasteur Hospital, Cardiology  
MOCERI, Pamela; Université Côte d’Azur, UR2CA, CHU de Nice, Cardiology Department  
Squara, Fabien; Hopital Pasteur, Cardiology |
| <b>Primary Subject Heading</b> | Cardiovascular medicine |
| Secondary Subject Heading: | Emergency medicine, Epidemiology, Global health, Intensive care, Respiratory medicine |
| Keywords: | Echocardiography < CARDIOLOGY, Adult cardiology < CARDIOLOGY, Thromboembolism < CARDIOLOGY |
I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author’s Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.
Is pulmonary embolism recurrence linked with the severity of the first event? A French retrospective cohort study.

Short title: PE severity and recurrence risk

Emile FERRARI, MD\textsuperscript{a}; Etienne FOURRIER, MD\textsuperscript{a}; Florian ASARISI, MD\textsuperscript{a}; Nathan HEME, MD\textsuperscript{a}; Nassim REDJIMI, MD\textsuperscript{a}; Nathalie BERKANE, MD\textsuperscript{b}; Mohamed LABBAOUI, MD\textsuperscript{a}; Jean Philippe BREITTMAYER, PhD\textsuperscript{a}; Sok Sithikun BUN, MD PhD\textsuperscript{a}; Pamela MOCERI, MD PhD\textsuperscript{a, c}; Fabien SQUARA, MD\textsuperscript{a, c}.

\textsuperscript{a} Cardiology Department, Centre Hospitalier Universitaire de Nice, Nice, France
\textsuperscript{b} Cardiology Department, Centre Hospitalier de Cannes, Cannes, France
\textsuperscript{c} UR2CA, Université Côte d’Azur, Nice, France

**Corresponding author:** Prof. Emile FERRARI – CHU de Nice, Cardiology Department

30, Avenue de la voie romaine - CS 51069 - 06001 Nice Cedex 1, France. e-mail: ferrari.e@chu-nice.fr

Conflicts of Interest: None

No previous presentation / abstract/ publication

Key words: pulmonary embolism. Epidemiology. Echocardiography. Biomarkers.

**Word count:** 2041
Abstract.

Objectives: Severity of a first pulmonary embolism (PE) is sometimes proposed as a criterion for prolonging anticoagulant treatment. However, little evidence supports this idea. We attempted to determine the connection between severity of first PE and the risk of recurrence.

Participants: Patients admitted with PE between 2012 and 2018 and for whom anticoagulant treatment had been discontinued were followed. PEs were classified according to severity into 2 groups: those with associated cardiac involvement (biomarkers and right ventricular dysfunction) and those with no cardiac involvement. Recurrence-free survivals were estimated using the Kaplan Meier method and compared using the Log Rank test.

Results: 417 PEs (186 with cardiac involvement) were followed for a least one year after discontinuation of treatment with a mean follow-up of: 3.5 ±1.9 years. 72 patients (17.3%) experienced venous thromboembolism recurrence: 24 (5.8%), 44 (12 %) and 72 (28.3 %) respectively, at 1, 2 and 5 years. In 63 patients (88%), recurrence was a PE. Mean time to onset of recurrence was 24.9 ±19.9 months. At 5 years, the recurrence rate was higher when the first PE was severe: p=0.043. When the first PE was unprovoked, no difference is found (p=0.27). In contrast, in patients with provoked PE, the recurrence rate is higher when the first PE event was severe: p=0.032. Multivariate analysis demonstrate that PE severity is an independent factor of recurrence (HR 1.634 [1.015-2.632], p=0.043).

Conclusion: We report for the first time a possible link between a higher recurrence rate and the severity of the first PE, with a recurrence rate of 9% vs 3% and of 35.5% vs 26% at 1 and 5 years respectively. This result which must be confirmed in a dedicated prospective trial could become an important criterion for the duration of anticoagulant therapy after a PE.

Trial registration: NCT04980924
Contributor ship statement:

EF and EF wrote the protocol and designed the study.

EF, NR, NB, ML, SB, PM followed up patients who were all reviewed with a long follow-up.

EF, FA, NH collected the data.

JP B and FS did the statistics.
Strengths and limitations:

- Little is known about the severity of PE and the risk of recurrence.
- This is the first time such a link is investigated.
- This study is a retrospective analysis of prospectively collected data.
- Our study is not randomized.
- The exclusion of patients who were long-term anticoagulated may have skewed the results of the non-provoked PEs sub-group.
**Background**

After the acute event, the choice of the duration of treatment is one of the main problems in the management of a first PE. Currently, provoked versus non-provoked circumstance is the main criterion used to determine treatment duration. Alongside this main criterion, other factors can also be taken into account such as bleeding risk, sex, blood group, persistence of a venous clot or the end-of-treatment D-dimers level\(^1\). Some practitioners consider first PE severity as a criterion likely to extend treatment duration. However, very few findings in the literature corroborate this idea.

**Objective and methods**

Drawing on our regional database\(^7\), we made an assessment of the connection between first PE severity and the risk of recurrence of VTE events. All patients hospitalized for PE from 2012 to 2018 were followed. Only patients whose treatment had been discontinued and for which we had a minimum 12-month follow-up were included. Consequently, patients requiring long-term anticoagulant treatment were excluded, along with patients with active cancer.

In accordance with the literature\(^8\), provoked PE was defined as PE which happened within three months of a surgery, a trauma, a significant immobility, pregnancy, a severe thrombophilia, the use of the combined contraceptive pill, hormone replacement therapy or know thrombogenic treatment. Unprovoked PE was defined as PE for which no transient risk factor or medication was involved. This classification was systematically verified at the one month follow-up visit, because new elements, often provided by the family, can highlight unreported aetiologies during the hospitalization of patients.

In our patients care, a first echocardiography is done upon admission, as well as a venous echo-doppler and biomarkers measurement. Biomarkers are repeated at H12, H24 and H48. In this cohort, 99 % of
patients were treated with direct oral anticoagulation treatment, namely rivaroxaban or apixaban with a 21 or 7 days loading dose respectively, then with adapted dosages. Patients were divided into two groups:

1) PE with cardiac involvement: in the presence of hemodynamic instability, increased cardiac biomarkers: Troponin I (Tp) > 70 ng/l and/or BNP > 100 pg/ml and/or right ventricular (RV) dysfunction corresponding to intermediate or high-risk PE in the European Society of Cardiology (ESC) classification. High-sensitivity Tp and BNP were measured with Siemens Centaur® and the Alere Triage BNP kit (Beckman Coulter®), respectively. The positivity threshold was 70 ng/l for Tp and 100 pg/ml for BNP. RV dysfunction was defined by echocardiography when a right-to-left ventricular end-diastolic diameter ratio > 0.9 in the apical four-chamber view or > 0.7 in the parasternal long-axis view, a tricuspid annular plane systolic excursion (TAPSE) < 16 mm or a tricuspid annular peak systolic velocity (S'-DTI) < 10 cm/s were observed. It should be noted that these PEs with cardiac involvement combined the high-risk and intermediate-risk classifications of the ESC guidelines.

2) PE with no cardiac involvement when none of the above-mentioned criteria were present corresponding to low-risk PE according to the ESC classification.

All chest CT-scans were reread by one radiology expert blinded to the first reading. Special emphasis was placed on eliminating patients with pre-existing pulmonary hypertension as revealed by the patient’s medical history or a search for specific signs on the initial scan such as the presence of arterial webs, mural thrombi or a mosaic parenchymal perfusion.

All patients who have had a PE are systematically followed in our department and seen after 1, 3 or 6 months then once a year. Recurrences were determined by a new symptomatic venous thrombotic event or by a symptomatic PE confirmed by diagnostic imaging which had to show a new clot along with positive D-Dimer values. We took into account the age of the patients to construe the D-Dimer values.
If patients presented several recurrences during follow-up, only the first was taken into account. A minimum 12-month follow-up was required although a recurrence within this 12-month period was considered as an event. Mean follow-up was 3.5 ±1.9 years. The causes of deaths which happened during follow–up could not be specified. Our study is in accordance with law n78-17 « Information, technology and freedom » of 6th January 1978 (modified by the new act dated 6th August 2004) and with the EU 2016/679 European Parliament and the 27 April 2016 Council regulation, applicable from May 25th of 2018 (GDPR). Our data base, has been registered as NCT04980924.

**Patient and public involvement:** This study being a retrospective analysis of prospectively collected data it was not suitable for a partnering with patients, their careers, support networks, and the public. Patients were not involved in this study.

**Statistical analysis:**

All statistical analyses were performed using SPSS software (Statistical Package for Social Science software, version 20, Chicago, Illinois, USA). Quantitative variables were expressed as medians and confidence intervals and qualitative variables as counts and percentages. Quantitative variables were compared using the Mann Whitney U test and qualitative variables were compared using the Chi2 test. Recurrence-free survivals were estimated using the Kaplan Meier method and compared using the Log-Rank test. Cox proportional hazards regression models were fitted to estimate HRs and 95% CIs to assess the relationship between baseline clinical characteristics and recurrences.

**Results**

Between 2012 and 2018, 1080 patients were hospitalized for PE confirmed by CT-scan. One hundred sixty-four (164) patients had a history of VTE and had received long-term treatment; 113 had active
neoplasia, 104 supraventricular arrhythmia requiring anticoagulant treatment and 91 a cause making follow-up impossible (Figure 1: Flow chart). In all, 417 patients with a follow-up exceeding 12 months after discontinuation of their anticoagulation treatment were included. Among these, 231 had presented PE without cardiac involvement and 186 PE with cardiac involvement (165 intermediate risk PE and 21 high-risk PE). The cohort’s initial characteristics are summarized in Table 1.

A factor explaining the first PE event was found in 212 (50.8%) patients. Associated deep vein thrombosis (DVT) was observed in 186 (44.6%) patients. All provoked PE were treated for 3 months. All unprovoked PE were treated for at least 6 months. Mean treatment duration was 5.18 ±2.3 months. Twenty-one patients (5%) received thrombolysis. Patient characteristics according to the severity of the initial clinical presentation are shown in Table 2. Patients in the PE group with cardiac involvement were more often diabetic: 34/186 (18%) vs 21/231 (9%), more often presented blood clots in the lower limbs: 96/186 (51%) vs 90/231 (39%) and averaged longer hospital stays (7.3 ±4 days vs 3.7 ±3 days) than patients without cardiac involvement.

Among the entire cohort, 72 patients (17.3%) presented VTE recurrence. The VTE recurrence rate after discontinuation of anticoagulation was 5.8% (n=24) the first year, 12% (n=44) at 2 years and 28.3% (n=72) at 5 years. In patients experiencing recurrence, 88% (n=63) suffered PE and 12% (n=9) suffered proximal DVT. Mean time to onset of recurrence was 24.9 ± 19.9 months. Kaplan Meier analysis of the entire cohort shows the survival rate of recurrence-free patients according to initial severity over a 5-year follow-up (Fig. 2). The recurrence-free survival rate was significantly higher when the first PE was non-severe p=0.043. Twelve months after completion of the anticoagulant treatment, the recurrence rate was 7/231 (3%), in the non-cardiac involvement group versus 17/186 (9.1%), in the cardiac involvement group: p=0.007.

Multivariate analysis using Cox regression (Table 3) demonstrate that PE with cardiac involvement is an independent factor of recurrence (HR 1.634 [1.015-2.632], p=0.043) as well as family history of PE.
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
PE could be explained by the fact that we maintained anticoagulation treatment in patients at higher risk of recurrence and consequently these patients were not included in our analysis. It is also possible that the high rate of spontaneous unprovoked PE recurrences conceals the impact of the severity factor. In the literature, the only data that can come close to our result is that of Grifoni et al 17 who reported a higher rate of recurrence when, after hospitalisation for PE, a RV dysfunction was still present at discharge from hospital.

The human physiological coagulation system is believed to protect us against the risk of thrombosis. The formation of venous clots in risky situations is not the rule. When a venous clot occurs, our coagulation-fibrinolysis system is supposed to control the situation by limiting its spread. The formation of a large amount of clots, and hence the occurrence of severe PE, could mean that control by the physiological coagulation system is even more failing. It could also provide additional, hitherto unknown, information on a greater propensity for recurrence.

In the literature, the recurrence risk of a provoked PE is deemed to be sufficiently low not to require long-term treatment. Nevertheless, the risk is still much higher than in a control population. The survey of the literature by Iorio et al 18 covering 2268 provoked PE with transitory risk shows a mean 0.7% annual recurrence rate after surgery but a 3.3% rate for patients as a whole and a 4.2% annual recurrence rate for non-surgical transitory risk factors. These two latter rates are close to the findings for unprovoked thromboembolic events. Our results indicate that in these provoked PE, an over-risk of recurrence could be associated with the severity of the initial event 2,19-21.

Our study was a retrospective analysis of prospectively collected data. It deserves to be confirmed in a dedicated prospective study.

**Conclusion:** In this cohort study, we highlight a possible link between the severity of a first PE and the risk of a subsequent recurrence. The provoked status of PE may not shield against a high recurrence rate when the first event was severe. These findings justify a prospective study designed to confirm
this relationship which could change the way we determine the duration of anticoagulation treatment after a first PE.
**Funding statement:** None

**Ethics statement:** Our study is in accordance with law n78-17 « Information, technology and freedom » of 6th January 1978 (modified by the new act dated 6th August 2004) and with the EU 2016/679 European Parliament and the 27 April 2016 Council regulation, applicable from May 25th of 2018 (GDPR). Our data base, has been registered as NCT04980924. This is a non-interventional retrospective cohort study.

**Data Availability:** All data relevant to the study are included in the article.
References

1. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. *N Engl J Med*. 2004;350(25):2558-2563.

2. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. *Haematologica*. 2007;92(2):199-205.

3. Linnemann B, Zgouras D, Schindewolf M, Schwonberg J, Jarosch-Preusche M, Lindhoff-Last E. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. *Blood Coagul Fibrinolysis Int J Haemost Thromb*. 2008;19(2):159-165.

4. Baudouy D, Moceri P, Chiche O, et al. B blood group: A strong risk factor for venous thromboembolism recurrence. *Thromb Res*. 2015;136(1):107-111.

5. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. *N Engl J Med*. 2006;355(17):1780-1789.

6. Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. *JAMA*. 2003;290(8):1071-1074.
7. Ferrari E, Baudouy M, Cerboni P, et al. Clinical epidemiology of venous thromboembolic disease. Results of a French Multicentre Registry. *Eur heart j* 1997; 18: 685-691.

8. Kearon C, Ageno W, Cannegieter SC, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. *J Thromb Haemost* 2016;14:1480-3.

9. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J.* 2020;41(4):543-603.

10. Kearon C, Iorio A, Palareti G, Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. *J Thromb Haemost JTH.* 2010;8(10):2313-2315.

11. Tromeur C, Sanchez O, Presles E, et al. Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial. *Eur Respir J.* 2018;51(1):1701202

12. Cohen AT, Gitt AK, Bauersachs R, et al. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. *Thromb Haemost.* 2017;117(7):1326-1337.
13. Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. *BMJ*. 2019;366:l4363.

14. Martinez C, Cohen AT, Bamber L, Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. *Thromb Haemost*. 2014;112(2):255-263.

15. Albertsen IE, Nielsen PB, Søgaard M, et al. Risk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. *Am J Med*. 2018;131(9):1067-1074.e4.

16. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. *J Thromb Haemost JTH*. 2010;8(11):2436-2442.

17. Grifoni S, Vanni S, Magazzini S, et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. *Arch Intern Med*. 2006;166(19):2151-2156.

18. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. *Arch Intern Med*. 2010;170(19):1710-1716.

19. Prins MH, Lensing AWA, Prandoni P, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. *Blood Adv*. 2018;2(7):788-796.
20. Ensor J, Riley RD, Moore D, Snell KIE, Bayliss S, Fitzmaurice D. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. *BMJ Open*. 2016;6(5):e011190.

21. Bikdeli B, Jimenez D, Hawkins M, et al. Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). *Thromb Haemost*. 2018;118(1):214-224.
Table 1: Initial cohort characteristics

| Overall population | N = 417 | % |
|--------------------|---------|---|
| Sex F/M, n (%)     | 221     | 53% |
| Age, years (median, [IC]) | 65 , [63-67] |
| Arterial hypertension, n (%) | 179 | 43% |
| Obesity, n (%)     | 74      | 18% |
| Dyslipidemia, n (%)| 109     | 26% |
| Diabetes, n (%)    | 55      | 13% |
| Smoking, n (%)     | 110     | 26% |
| History of stroke, n (%) | 26 | 6% |
| Inflammatory disease, n (%) | 33 | 8% |
| Psychiatric pathology, n (%) | 83 | 20% |
| Provoked, n (%)    | 212     | 51% |
| Associated DVT, n (%) | 186 | 45% |
| Proximal DVT       | 92      | 22% |
| Distal DVT         | 94      | 23% |
| Thrombolysis, n (%)| 21      | 5% |
| Aspirin treatment  | 68      | 16.3% |
| Statin treatment   | 42      | 10% |
| Psychotropic medication | 76 | 18.2% |
| Duration of hospital stay, days (median, [IC]) | 5 [4-5] |
| Initial anticoagulation duration, months (median, [IC]) | 6 [6-6] |
| Follow-up period, months (median, [IC]) | 36 [33 – 40] |
| VTE recurrence, n (%) | 72 | 18% |
| - PE, n (% of recurrence) | 63 | 88% |
| - DVT, n (% of recurrence) | 9 | 12% |
| Time to recurrence, in months, (median, [IC]) | 18.5 [14-24] |

SD = Standard Deviation, DVT = Deep Vein Thrombosis, VTE = Venous Thromboembolism, PE = Pulmonary Embolism
Table 2: Initial characteristics of PE groups without and with cardiac involvement

|                                | PE without cardiac involvement | PE with cardiac involvement | P-value |
|--------------------------------|--------------------------------|-----------------------------|---------|
| **Sex F/M, n (%)**             | 113 (48.9)                     | 108 (58.1)                  | 0.074   |
| **Age, years (mean ± SD)**     | 61 ± 17.2                      | 63 ± 15.5                   | 0.12    |
| **Arterial hypertension, n (%)**| 90 (39)                        | 89 (48)                     | 0.068   |
| **Obesity, n (%)**             | 43 (19)                        | 31 (17)                     | 0.622   |
| **Dyslipidemia, n (%)**        | 53 (23)                        | 56 (30)                     | 0.09    |
| **Diabetes, n (%)**            | 21 (9)                         | 34 (18)                     | 0.006   |
| **Smoking, n (%)**             | 72 (31)                        | 38 (20)                     | 0.012   |
| **History of stroke, n (%)**   | 10 (4)                         | 16 (8.6)                    | 0.073   |
| **Inflammatory disease, n (%)**| 17 (7)                         | 16 (8.6)                    | 0.187   |
| **Psychiatric pathology, n (%)**| 45 (20)                      | 38 (20)                     | 0.809   |
| **Provoked, n (%)**            | 112 (49)                       | 100 (54)                    | 0.284   |
| **Associated DVT, n (%)**      | 90 (39)                        | 96 (52)                     | 0.01    |
| **Length of hospital stay, days (mean ± SD)** | 4.7 ± 3                      | 7.3 ± 4                     | 0.004   |
| **Tp (ng/l)**                  | 29.1 ± 16                      | 240 ± 237                   | 0.0001  |
| **BNP (pg/l)**                 | 45 ± 21                        | 243.2 ± 106                 | 0.0001  |
| **RV/LV**                      | 0.62 ± 0.07                    | 0.96 ± 0.05                 | 0.01    |
| **Duration in months of initial anticoagulation** | 5.18 ± 2.4                | 5.2 ± 2.3                   | 0.417   |

SD = Standard Deviation, DVT = Deep Vein Thrombosis, Tp = Troponin, BNP = Brain Natriuretic Peptide, RV/LV = right-to-left ventricular end-diastolic diameter ratio > 0.9 in the apical four-chamber view
Table 3. Multivariate analysis using Cox regression for the risk of recurrence.

| Clinical factor                      | Hazard Ratio | P value | 95% CI       |
|--------------------------------------|--------------|---------|--------------|
| Female gender                        | 1.022        | 0.927   | [0.636 - 1.644] |
| Family history of PE                 | 2.851        | 0.003   | [1.422 - 5.716] |
| Psychotropic medication              | 1.252        | 0.471   | [0.679 - 2.309] |
| Provoked PE                          | 0.506        | 0.007   | [0.308 - 0.831] |
| PE with cardiac involvement          | 1.634        | 0.043   | [1.015 - 2.632] |
| Associated DVT                       | 1.216        | 0.471   | [0.679 - 2.309] |
| Anticoagulation duration after PE    | 1.023857     | 0.196   | [0.988 - 1.061] |

DVT = Deep Vein Thrombosis, VTE = Venous Thromboembolism, PE = Pulmonary Embolism
Figure legend:

**Figure 1:** Study flow-chart

**Figure 2:** Recurrence-free survival for VTE according to severity of first PE

**Figure 3:** Recurrence-free survival following provoked PE according to severity of first PE

**Figure 4:** Recurrence-free survival following unprovoked PE according to severity of first PE
Figure 1

Patients hospitalized with PE from 2012 to 2018
n = 1080

Pre-selected patients n = 671

Included patients n = 417

Low-risk PE n = 231

Intermediate-risk PE n = 165

High-risk PE n = 21

PE with no cardiac involvement n = 231

PE with cardiac involvement n = 186

Non-included patients N = 409
- History of VTE n = 164
- Active neoplasia n = 113
- Supra-ventricular arrhythmia n = 104
- Thrombophilia n = 28

Excluded patients N = 254
- Dementia n = 91
- Lost to follow-up n = 57
- Deceased during the first 12 months n = 44
- Other (PHI group IV, advanced degenerative neuropathy or long-term bedridden, or patient wishing to maintain long-term anticoagulation) n = 62
Figure 2

![Graph showing recurrence-free survival rate over time since discontinuation of anticoagulant with and without cardiac involvement. The graphs show a significant difference in survival rates with a p-value of 0.043.]

- PE without cardiac involvement:
  - 231 (0)
  - 224 (7)
  - 148 (20)
  - 104 (26)
  - 68 (29)
  - 39 (35)

- PE with cardiac involvement:
  - 186 (0)
  - 169 (17)
  - 98 (24)
  - 72 (27)
  - 34 (34)
  - 20 (37)
Figure 3

![Graph showing recurrence-free survival rates for PE with and without cardiac involvement.]

| Time since discontinuation of anticoagulant (years) | PE without cardiac involvement | PE with cardiac involvement |
|-----------------------------------------------------|--------------------------------|-----------------------------|
| 0                                                   | 112 (0)                        | 100 (0)                     |
| 1                                                   | 110 (2)                        | 91 (9)                      |
| 2                                                   | 74 (14)                        | 56 (11)                     |
| 3                                                   | 49 (6)                         | 37 (14)                     |
| 4                                                   | 34 (8)                         | 18 (17)                     |
| 5                                                   | 19 (10)                        | 13 (17)                     |

p = 0.032
Figure 4

![Graph showing recurrence-free survival rate over time since discontinuation of anticoagulant. The graph compares patients with and without cardiac involvement. The y-axis represents the recurrence-free survival rate (%), and the x-axis represents time since discontinuation of anticoagulant (years). The graph includes data points for different time intervals: 0, 1, 2, 3, 4, and 5 years. The legend indicates two groups: PE without cardiac involvement and PE with cardiac involvement. The p-value is 0.268.]

- PE without cardiac involvement:
  - 0 years: 119 (0)
  - 1 year: 114 (5)
  - 2 years: 75 (15)
  - 3 years: 54 (20)
  - 4 years: 34 (22)
  - 5 years: 19 (25)

- PE with cardiac involvement:
  - 0 years: 86 (0)
  - 1 year: 78 (8)
  - 2 years: 42 (13)
  - 3 years: 34 (14)
  - 4 years: 15 (17)
  - 5 years: 7 (20)
Is pulmonary embolism recurrence linked with the severity of the first event? A French retrospective cohort study.

| Journal:            | BMJ Open       |
|---------------------|----------------|
| Manuscript ID:      | bmjopen-2021-050910.R2 |
| Article Type:       | Original research |
| Date Submitted by the Author: | 13-Sep-2021 |
| Complete List of Authors: | Ferrari, Emile; Centre Hospitalier Universitaire de Nice Hospital Pasteur, Cardiology Department
Fourrier, Etienne; University Hospital Centre Nice Pasteur Hospital, Cardiology
Asarisi, Florian; University Hospital Centre Nice Pasteur Hospital, Cardiology
Heme, Nathan; University Hospital Centre Nice Pasteur Hospital, Cardiology
Redjimi, Nassim; University Hospital Centre Nice Pasteur Hospital, Cardiology
Berkane, Nathalie; Centre Hospitalier de Cannes, Cardiology
Labbaoui, Mohamed; CHU Nice, Cardiology
Breittmayer, Jean Philippe; University Hospital Centre Nice Pasteur Hospital, Cardiology
Bun, Sok Sithikun; University Hospital Centre Nice Pasteur Hospital, Cardiology
MOCERI, Pamela; Université Côte d'Azur, UR2CA, CHU de Nice, Cardiology Department
Squara, Fabien; Hopital Pasteur, Cardiology |
| Primary Subject Heading: | Cardiovascular medicine |
| Secondary Subject Heading: | Emergency medicine, Epidemiology, Global health, Intensive care, Respiratory medicine |
| Keywords: | Echocardiography < CARDIOLOGY, Adult cardiology < CARDIOLOGY, Thromboembolism < CARDIOLOGY |
I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author’s Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.
Is pulmonary embolism recurrence linked with the severity of the first event? A French retrospective cohort study.

Short title: PE severity and recurrence risk

Emile FERRARI, MD\textsuperscript{a}; Etienne FOURRIER, MD\textsuperscript{a}; Florian ASARISI, MD\textsuperscript{a}, Nathan HEME, MD\textsuperscript{a};
Nassim REDJIMI, MD\textsuperscript{a}; Nathalie BERKANE, MD\textsuperscript{b}; Mohamed LABBAOUI, MD\textsuperscript{a};
Jean Philippe BREITTMAYER, PhD\textsuperscript{a}; Sok Sithikun BUN, MD PhD\textsuperscript{a},
Pamela MOCERI, MD PhD\textsuperscript{a,c}; Fabien SQUARA, MD\textsuperscript{a,c}.

\textsuperscript{a} Cardiology Department, Centre Hospitalier Universitaire de Nice, Nice, France
\textsuperscript{b} Cardiology Department, Centre Hospitalier de Cannes, Cannes, France
\textsuperscript{c} UR2CA, Université Côte d’Azur, Nice, France

**Corresponding author:** Prof. Emile FERRARI – CHU de Nice, Cardiology Department

30, Avenue de la voie romaine - CS 51069 - 06001 Nice Cedex 1, France. e-mail: ferrari.e@chu-nice.fr

Conflicts of Interest: None

No previous presentation / abstract/ publication

Key words: pulmonary embolism. Epidemiology. Echocardiography. Biomarkers.

Word count: \textbf{2041}
Abstract.

Objectives: Severity of a first pulmonary embolism (PE) is sometimes proposed as a criterion for prolonging anticoagulant treatment. However, little evidence supports this idea. We attempted to determine the connection between severity of first PE and the risk of recurrence.

Participants: Patients admitted with PE between 2012 and 2018 and for whom anticoagulant treatment had been discontinued were followed. PEs were classified according to severity into 2 groups: those with associated cardiac involvement (increased cardiac biomarker(s) and/or echocardiographic right ventricular dysfunction) and those with no cardiac involvement which were classified as non-severe. Recurrence-free survivals were estimated using the Kaplan Meier method and compared using the Log Rank test.

Results: 417 PEs (186 with cardiac involvement) were followed for a least one year after discontinuation of treatment with a mean follow-up of: 3.5 ± 1.9 years. 72 patients (17.3%) experienced venous thromboembolism recurrence: 24 (5.8%), 44 (12 %) and 72 (28.3 %) respectively, at 1, 2 and 5 years. In 63 patients (88%), recurrence was a PE. Mean time to onset of recurrence was 24.9 ± 19.9 months. At 5 years, the recurrence rate was higher when the first PE was associated with cardiac involvement p=0.043. In contrast, in patients with provoked PE, the recurrence rate is higher when the first PE event was associated with cardiac involvement: p=0.032. Multivariate analysis demonstrate that PE severity is an independent factor of recurrence (HR 1.634 [1.015-2.632], p=0.043).

Conclusion: We report for the first time a possible link between a higher recurrence rate and the severity of the first PE. This result which must be confirmed in a dedicated prospective trial could become an important criterion for the duration of anticoagulant therapy after a PE.

Trial registration: NCT04980924
Strengths and limitations:

- Little is known about the severity of PE and the risk of recurrence.
- This is the first time such a link is investigated.
- This study is a retrospective analysis of prospectively collected data.
- Only symptomatic references were taken into account.
- The exclusion of patients who were long-term anticoagulated may have skewed the results of the non-provoked PEs sub-group.
Background

After the acute event, the choice of the duration of treatment is one of the main problems in the management of a first PE. Currently, provoked versus non-provoked circumstance is the main criterion used to determine treatment duration. Alongside this main criterion, other factors can also be taken into account such as bleeding risk, sex, blood group, persistence of a venous clot or the end-of-treatment D-dimers level. Some practitioners consider first PE severity as a criterion likely to extend treatment duration. However, very few findings in the literature corroborate this idea.

Objective and methods

Drawing on our regional database, we made an assessment of the connection between first PE severity and the risk of recurrence of VTE events. All patients hospitalized for PE from 2012 to 2018 were followed. Only patients whose treatment had been discontinued and for which we had a minimum 12-month follow-up were included. Consequently, patients requiring long-term anticoagulant treatment were excluded, along with patients with active cancer.

In accordance with the literature, provoked PE was defined as PE which happened within three months of a surgery, a trauma, a significant immobility, pregnancy, a severe thrombophilia, the use of the combined contraceptive pill, hormone replacement therapy or know thrombogenic treatment. Unprovoked PE was defined as PE for which no transient risk factor or medication was involved. This classification was systematically verified at the one month follow-up visit, because new elements, often provided by the family, can highlight unreported aetiologies during the hospitalization of patients.

In our patients care, a first echocardiography is done upon admission, as well as a venous echo-doppler and biomarkers measurement. Biomarkers are repeated at H12, H24 and H48. In this cohort, 99 % of
patients were treated with direct oral anticoagulation treatment, namely rivaroxaban or apixaban with a 21 or 7 days loading dose respectively, then with adapted dosages.

Patients were divided into two groups:

1) PE with cardiac involvement: in the presence of hemodynamic instability, increased cardiac biomarkers: Troponin I (Tp) > 70 ng/l and/or BNP > 100 pg/ml and/or right ventricular (RV) dysfunction corresponding to intermediate or high-risk PE in the European Society of Cardiology (ESC) classification. High-sensitivity Tp and BNP were measured with Siemens Centaur® and the Alere Triage BNP kit (Beckman Coulter®), respectively. The positivity threshold was 70 ng/l for Tp and 100 pg/ml for BNP. RV dysfunction was defined by echocardiography when a right-to-left ventricular end-diastolic diameter ratio > 0.9 in the apical four-chamber view or > 0.7 in the parasternal long-axis view, a tricuspid annular plane systolic excursion (TAPSE) < 16 mm or a tricuspid annular peak systolic velocity (S'-DTI) < 10 cm/s were observed. It should be noted that these PEs with cardiac involvement combined the high-risk and intermediate-risk classifications of the ESC guidelines.

2) PE with no cardiac involvement when none of the above-mentioned criteria were present corresponding mainly to low-risk PE according to the ESC classification. These PE were classified as non-severe in our study.

All chest CT-scans were reread by one radiology expert blinded to the first reading. Special emphasis was placed on eliminating patients with pre-existing pulmonary hypertension as revealed by the patient’s medical history or a search for specific signs on the initial scan such as the presence of arterial webs, mural thrombi or a mosaic parenchymal perfusion.

All patients who have had a PE are systematically followed in our department and seen after 1, 3 or 6 months then once a year. Recurrences were determined by a new symptomatic venous thrombotic event or by a symptomatic PE confirmed by diagnostic imaging which had to show a new clot along
with positive D-Dimer values. We took into account the age of the patients to construe the D-Dimer values.

If patients presented several recurrences during follow-up, only the first was taken into account. A minimum 12-month follow-up was required although a recurrence within this 12-month period was considered as an event. Mean follow-up was 3.5 ±1.9 years. The causes of deaths which happened during follow-up could not be specified. Our study is in accordance with law n78-17 « Information, technology and freedom » of 6th January 1978 (modified by the new act dated 6th August 2004) and with the EU 2016/679 European Parliament and the 27 April 2016 Council regulation, applicable from May 25th of 2018 (GDPR). Our data base, has been registered as NCT04980924.

Patient and public involvement: This study being a retrospective analysis of prospectively collected data it was not suitable for a partnering with patients, their careers, support networks, and the public. Patients were not involved in this study.

Statistical analysis:

All statistical analyses were performed using SPSS software (Statistical Package for Social Science software, version 20, Chicago, Illinois, USA). Quantitative variables were expressed as mean and standard deviation when the distribution was normal, or median and confidence interval when the distribution was not normal. The normal distribution of quantitative variables was assessed using the Kolmogorov-Smirnov test. Qualitative variables were expressed as counts and percentages. Quantitative variables were compared using the Mann Whitney U test, and qualitative variables were compared using the Chi2 test. Recurrence-free survivals were estimated using the Kaplan Meier method and compared using the Log-Rank test. Cox proportional hazards regression models were fitted to estimate HRs and 95% CIs to assess the relationship between baseline clinical characteristics and recurrences. A \( P \leq 0.05 \) was considered significant.
Results

Between 2012 and 2018, 1080 patients were hospitalized for PE confirmed by CT-scan. One hundred sixty-four (164) patients had a history of VTE and had received long-term treatment; 113 had active neoplasia, 104 supraventricular arrhythmia requiring anticoagulant treatment and 91 a cause making follow-up impossible (Figure 1: Flow chart). In all, 417 patients with a follow-up exceeding 12 months after discontinuation of their anticoagulation treatment were included. Among these, 231 had presented PE without cardiac involvement and 186 PE with cardiac involvement (165 intermediate risk PE and 21 high-risk PE). The cohort’s initial characteristics are summarized in Table 1.

A factor explaining the first PE event was found in 212 (50.8%) patients. Associated deep vein thrombosis (DVT) was observed in 186 (44.6%) patients. All provoked PE were treated for 3 months. All unprovoked PE were treated for at least 6 months. Mean treatment duration was 5.18 ±2.3 months. Twenty-one patients (5%) received thrombolysis. Patient characteristics according to the severity of the initial clinical presentation are shown in Table 2. Patients in the PE group with cardiac involvement were more often diabetic: 34/186 (18%) vs 21/231 (9%), more often presented blood clots in the lower limbs: 96/186 (51%) vs 90/231 (39%) and averaged longer hospital stays (7.3 ±4 days vs 3.7 ±3 days) than patients without cardiac involvement.

Among the entire cohort, 72 patients (17.3%) presented VTE recurrence. The VTE recurrence rate after discontinuation of anticoagulation was 5.8% (n=24) the first year, 12% (n=44) at 2 years and 28.3% (n=72) at 5 years. In patients experiencing recurrence, 88% (n=63) suffered PE and 12% (n=9) suffered proximal DVT. Mean time to onset of recurrence was 24.9 ± 19.9 months. Kaplan Meier analysis of the entire cohort shows the survival rate of recurrence-free patients according to initial severity over a 5-year follow-up (Fig. 2). The recurrence-free survival rate was significantly higher when the first PE was non-severe p=0.043. Twelve months after completion of the anticoagulant treatment, the recurrence
rate was 7/231 (3%), in the non-cardiac involvement group versus 17/186 (9.1%), in the cardiac involvement group: \( p = 0.007 \).

In the multivariate analysis using Cox regression (Table 3) including cardiac involvement, gender, family history of VTE, psychotropic medication, unprovoked PE, associated DVT and duration of anticoagulation; cardiac involvement (HR 1.634 [1.015-2.632], \( p = 0.043 \)) and family history of VTE (HR 2.851 [1.422-5.716], \( p = 0.003 \)) were independent risk factors, whereas as provoked PE is associated with less recurrence (HR 0.506 [0.308-0.831], \( p = 0.007 \)).

Figure 3 compares the survival rates with no VTE recurrence according to the provoked or unprovoked nature of the first PE. In the sub-group of patients presenting an unprovoked PE, Kaplan Meier analysis revealed no difference in recurrence rate according to first PE severity: \( p = 0.27 \). On the other hand, (Fig. 4), a higher recurrence rate was noted in the sub-group of patients with a severe provoked PE: \( p = 0.032 \). At 12 months, recurrence rates were, respectively, 2/112 (1.8%) when there was no initial cardiac involvement versus 9/100 (9%) when cardiac involvement was observed; \( p = 0.018 \).

Discussion

After the acute phase, the duration of anticoagulation treatment raises one of the major problems in PE management. Some features have been correlated with an added risk of recurrence and are taken into account when choosing a longer treatment. Other criteria are considered although their connection with increased risk of recurrence has not been formally proven\(^{10-12}\). However, to our knowledge, no study has assessed the benefits of pursuing anticoagulant treatment relative to first PE severity. We thought it would be useful to look for a relationship between the severity of the initial PE and the recurrence rate. In the present study including 417 patients followed for a mean of 42 months, the incidence of recurrence was similar to findings described in the literature. In 88% of cases, recurrence occurred at the same site as the first event. We also observed a well-known added risk of
recurrence in cases with unprovoked first PE. We confirm a statistical correlation between the risk of recurrence and the presence of DVT at the time of the first PE\textsuperscript{13-16}.

We describe for the first time a higher recurrence rate when the initial PE was severe with a recurrence rate of 9\% vs 3\% and 35.5\% vs 26\%, respectively, at 1 and 5 years: \( p=0.043 \). Unexpectedly, the correlation between PE severity and the risk of recurrence was stronger when PE was provoked: \( p=0.032 \). The lack of a relationship in our study between severity and recurrence among unprovoked PE could be explained by the fact that we maintained anticoagulation treatment in patients at higher risk of recurrence and consequently these patients were not included in our analysis. It is also possible that the high rate of spontaneous unprovoked PE recurrences conceals the impact of the severity factor. In the literature, the only data that can come close to our result is that of Grifoni et al\textsuperscript{17} who reported a higher rate of recurrence when, after hospitalisation for PE, a RV dysfunction was still present at discharge from hospital.

The human physiological coagulation system is believed to protect us against the risk of thrombosis. The formation of venous clots in risky situations is not the rule. When a venous clot occurs, our coagulation-fibrinolysis system is supposed to control the situation by limiting its spread. The formation of a large amount of clots, and hence the occurrence of PE with cardiac involvement, could mean that control by the physiological coagulation system is even more failing. It could also provide additional, hitherto unknown, information on a greater propensity for recurrence.

In the literature, the recurrence risk of a provoked PE is deemed to be sufficiently low not to require long-term treatment. Nevertheless, the risk is still much higher than in a control population. The survey of the literature by Iorio et al\textsuperscript{18} covering 2268 provoked PE with transitory risk shows a mean 0.7\% annual recurrence rate after surgery but a 3.3\% rate for patients as a whole and a 4.2\% annual recurrence rate for non-surgical transitory risk factors. These two latter rates are close to the findings for unprovoked thromboembolic events. Our results indicate that in these provoked PE, an over-risk of recurrence could be associated with the severity of the initial event\textsuperscript{2,19-21}. 
Our study was a retrospective analysis of prospectively collected data. There are possible limitations; we report only symptomatic episodes, potential changes in risk factors over time (e.g. obesity, smoking...) could not be taken into account. Some known risk factors of recurrence were not considered in the multivariate analysis as high body mass index or high D-dimer level. Our conclusions cannot be applied to cancer patients or those needing long-term treatment since these patients were excluded from the study. Our results deserves to be confirmed in a dedicated prospective study.

**Conclusion:** In this cohort study, we highlight a possible link between the severity of a first PE and the risk of a subsequent recurrence. The provoked status of PE may not shield against a high recurrence rate when the first event was severe. These findings justify a prospective study designed to confirm this relationship which could change the way we determine the duration of anticoagulation treatment after a first PE.
Contributor statement: 

EF and EF wrote the protocol and the designed the study.

EF, NR, NB, ML, SB, PM followed up patients who were all reviewed with a long follow-up.

EF, FA, NH collected the data

JP B and FS did the statistics

Competing interests: None

Funding statement: None

Ethics statement: Our study is in accordance with law n78-17 « Information, technology and freedom » of 6th January 1978 (modified by the new act dated 6th August 2004) and with the EU 2016/679 European Parliament and the 27 April 2016 Council regulation, applicable from May 25th of 2018 (GDPR). Our data base, has been registered as NCT04980924. This is a non-interventional retrospective cohort study.

Data Availability: All data relevant to the study are included in the article.
References

1. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. *N Engl J Med*. 2004;350(25):2558-2563.

2. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. *Haematologica*. 2007;92(2):199-205.

3. Linnemann B, Zgouras D, Schindewolf M, Schwonberg J, Jarosch-Preusche M, Lindhoff-Last E. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. *Blood Coagul Fibrinolysis Int J Haemost Thromb*. 2008;19(2):159-165.

4. Baudouy D, Moceri P, Chiche O, et al. B blood group: A strong risk factor for venous thromboembolism recurrence. *Thromb Res*. 2015;136(1):107-111.

5. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. *N Engl J Med*. 2006;355(17):1780-1789.

6. Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. *JAMA*. 2003;290(8):1071-1074.
7. Ferrari E, Baudouy M, Cerboni P, et al. Clinical epidemiology of venous thromboembolic
disease. Results of a French Multicentre Registry. *Eur heart j* 1997; 18: 685-691.

8. Kearon C, Ageno W, Cannegieter SC, et al. Categorization of patients as having provoked or
unprovoked venous thromboembolism: guidance from the SSC of ISTH. *J Thromb Haemost*
2016;14:1480-3.

9. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and
management of acute pulmonary embolism developed in collaboration with the European
Respiratory Society (ERS). *Eur Heart J.* 2020;41(4):543-603.

10. Kearon C, Iorio A, Palareti G, Subcommittee on Control of Anticoagulation of the SSC of the
ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies:
recommendation for acceptable rates and standardized reporting. *J Thromb Haemost JTH.*
2010;8(10):2313-2315.

11. Tromeur C, Sanchez O, Presles E, et al. Risk factors for recurrent venous thromboembolism
after unprovoked pulmonary embolism: the PADIS-PE randomised trial. *Eur Respir J.*
2018;51(1):1701202

12. Cohen AT, Gitt AK, Bauersachs R, et al. The management of acute venous thromboembolism
in clinical practice. Results from the European PREFER in VTE Registry. *Thromb Haemost.*
2017;117(7):1326-1337.
13. Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366:l4363.

14. Martinez C, Cohen AT, Bamber L, Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost. 2014;112(2):255-263.

15. Albertsen IE, Nielsen PB, Søgaard M, et al. Risk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. Am J Med. 2018;131(9):1067-1074.e4.

16. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost JTH. 2010;8(11):2436-2442.

17. Grifoni S, Vanni S, Magazzini S, et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med. 2006;166(19):2151-2156.

18. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19):1710-1716.

19. Prins MH, Lensing AWA, Prandoni P, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv. 2018;2(7):788-796.
20. Ensor J, Riley RD, Moore D, Snell KIE, Bayliss S, Fitzmaurice D. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. *BMJ Open*. 2016;6(5):e011190.

21. Bikdeli B, Jimenez D, Hawkins M, et al. Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). *Thromb Haemost*. 2018;118(1):214-224.
Table 1: Initial cohort characteristics

| Overall population                       | N = 417 | %   |
|------------------------------------------|---------|-----|
| Sex F/M, n (%)                           | 221     | 53% |
| Age, years (median, [IC])                | 65, [63-67] |     |
| Arterial hypertension, n (%)             | 179     | 43% |
| Obesity, n (%)                           | 74      | 18% |
| Dyslipidemia, n (%)                      | 109     | 26% |
| Diabetes, n (%)                          | 55      | 13% |
| Smoking, n (%)                           | 110     | 26% |
| History of stroke, n (%)                 | 26      | 6%  |
| Inflammatory disease, n (%)              | 33      | 8%  |
| Psychiatric pathology, n (%)             | 83      | 20% |
| Provoked, n (%)                          | 212     | 51% |
| Associated DVT, n (%)                    | 186     | 45% |
| Proximal DVT                             | 92      | 22% |
| Distal DVT                               | 94      | 23% |
| Thrombolysis, n (%)                      | 21      | 5%  |
| Aspirin treatment                        | 68      | 16.3% |
| Statin treatment                         | 42      | 10% |
| Psychotropic medication                  | 76      | 18.2% |
| Duration of hospital stay, days (median, [IC]) | 5 [4-5] |     |
| Initial anticoagulation duration, months (median, [IC]) | 6 [6-6] |     |
| Follow-up period, months (median, [IC])  | 36 [33 – 40] |   |
| VTE recurrence, n (%)                    | 72      | 18% |
| - PE, n (% of recurrence)                | 63      | 88% |
| - DVT, n (% of recurrence)               | 9       | 12% |
| Time to recurrence, in months, (median, [IC]) | 18.5 [14-24] |   |

SD = Standard Deviation, DVT = Deep Vein Thrombosis, VTE = Venous Thromboembolism,
PE = Pulmonary Embolism
Table 2: Initial characteristics of PE groups without and with cardiac involvement

|                                | PE without cardiac involvement | PE with cardiac involvement | P-value |
|--------------------------------|--------------------------------|----------------------------|---------|
| **Sex F/M, n (%)**             | 113 (48.9)                     | 108 (58.1)                 | 0.074   |
| **Age, years (mean ± SD)**     | 61 ± 17.2                      | 63 ± 15.5                  | 0.12    |
| **Arterial hypertension, n (%)** | 90 (39)                        | 89 (48)                    | 0.068   |
| **Obesity, n (%)**             | 43 (19)                        | 31 (17)                    | 0.622   |
| **Dyslipidemia, n (%)**        | 53 (23)                        | 56 (30)                    | 0.09    |
| **Diabetes, n (%)**            | 21 (9)                         | 34 (18)                    | 0.006   |
| **Smoking, n (%)**             | 72 (31)                        | 38 (20)                    | 0.012   |
| **History of stroke, n (%)**   | 10 (4)                         | 16 (8.6)                   | 0.073   |
| **Inflammatory disease, n (%)** | 17 (7)                         | 16 (8.6)                   | 0.187   |
| **Psychiatric pathology, n (%)** | 45 (20)                      | 38 (20)                    | 0.809   |
| **Family history of VTE**      | 15 (6.5)                       | 12 (6.5)                   | 0.986   |
| **Provoked, n (%)**            | 112 (49)                       | 100 (54)                   | 0.284   |
| **Associated DVT, n (%)**      | 90 (39)                        | 96 (52)                    | 0.01    |
| **Length of hospital stay, days (mean ± SD)** | 4.7 ± 3                       | 7.3 ± 4                    | 0.004   |
| **Tp (ng/l)**                  | 17 [17-17]                     | 298 [206-376]              | 0.0001  |
| **BNP (pg/l)**                 | 30 [25-34]                     | 293 [241-327]              | 0.0001  |
| **RV/LV**                      | 0.62 ± 0.07                    | 0.96 ± 0.05                | 0.01    |
| **Duration in months of initial anticoagulation** | 5.18 ± 2.4                    | 5.2 ± 2.3                  | 0.417   |

SD = Standard Deviation, VTE: venous thromboembolic disease, DVT = Deep Vein

Thrombosis, Tp = Troponin, BNP = Brain Natriuretic Peptide, RV/LV = right-to-left ventricular end-diastolic diameter ratio > 0.9 in the apical four-chamber view.
Table 3. Multivariate analysis using Cox regression for the risk of recurrence.

| Clinical factor                        | Hazard Ratio | P value | 95% CI        |
|----------------------------------------|--------------|---------|---------------|
| Female gender                          | 1.022        | 0.927   | [0.636 - 1.644] |
| Family history of PE                   | 2.851        | 0.003   | [1.422 - 5.716] |
| Psychotropic medication                | 1.252        | 0.471   | [ 0.679 - 2.309] |
| Provoked PE                            | 0.506        | 0.007   | [0.308 - 0.831] |
| PE with cardiac involvement            | 1.634        | 0.043   | [ 1.015 - 2.632] |
| Associated DVT                         | 1.216        | 0.471   | [ 0.679 - 2.309] |
| Anticoagulation duration after PE      | 1.023857     | 0.196   | [0.988 - 1.061] |

DVT = Deep Vein Thrombosis, VTE = Venous Thromboembolism, PE = Pulmonary Embolism
Figure legend:

**Figure 1:** Study flow-chart

**Figure 2:** Recurrence-free survival for VTE according to severity of first PE

**Figure 3:** Recurrence-free survival following provoked PE according to severity of first PE

**Figure 4:** Recurrence-free survival following unprovoked PE according to severity of first PE
Figure 1: Study flow-chart
Figure 2: Recurrence-free survival for VTE according to severity of first PE
Figure 3: Recurrence-free survival following provoked PE according to severity of first PE

![Graph showing recurrence-free survival](image-url)
Figure 4: Recurrence-free survival following unprovoked PE according to severity of first PE